FDA
-
-
-
-
-
-
-
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
-
-
-
-
-
-
-
FDA grants Vanda formal hearing on HETLIOZ jet lag application
-
-
-
-
-
-
-
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovat
-
-
-
-
-
-
-
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
-
-
-
-
-
-
-
Vanda gets FDA extension for tradipitant motion sickness drug review
-
-
-
-
-
-
-
Vanda publishes study showing HETLIOZ improved sleep in insomnia patients
-
-
-
-
-
-
-
Federal appeals court overturns FDA denial of Vanda's jet lag drug
-
323,284 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

